SOUTH SAN FRANCISCO, Calif., April 2, 2015 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, today announced that the company will participate in two upcoming investor and medical conferences.

14th Annual Needham Healthcare Conference

Dai Chaplin, Ph.D., president and chief executive officer, will provide a corporate overview at the 14 th Annual Needham Healthcare Conference on April 15, 2015. The presentation will take place at 3:00 p.m. ET at The Westin NY Grand Central Hotel in New York, NY.

To listen to a live or an archived version of the webcast, please log on to the Company's website at Under the "Investors" tab, select the link to "Events & Presentations." A replay of the webcast will be available one hour after the conclusion of the live event.

Annual Meeting of the American Association of Cancer Research (AACR)

Poster presentations related to OXiGENE's early stage scientific programs will also be presented at the AACR Annual Meeting 2015 taking place April 18-22, 2015 at the Pennsylvania Convention Center in Philadelphia.

Details on the three preclinical poster presentations are as follows:
Title: Targeting the Microenvironment and Vasculature of Tumors to Improve Response to Radiation Administered Using a Dose and Schedule Equivalent to Those of a Stereotactic Radiation Treatment
Authors: Michael R. Horsman, Ph.D. and Thomas R. Wittenborn, Ph.D.,
  Aarhus University Hospital, Aarhus, Denmark
Abstract: 1796
Date/Time/Location: Monday, April 20, 2015, 8:00 AM – 12:00 PM (ET), Section 33
Title: Assessing the Effects of the Small Molecule Cathepsin L Inhibitor, KGP94: Combination with Radiotherapy and Evaluation of Antimetastatic Potential in Vivo 
Authors: Thomas R. Wittenborn, Ph.D., Michael R. Horsman, Ph.D.,
  Aarhus University Hospital, Aarhus, Denmark
Abstract: 4498
Date/Time/Location: Tuesday, April 21, 2015, 1:00 PM – 5:00 PM (ET), Section 31
Title: Role of Cathepsin L in Breast Cancer Angiogenesis 
Authors: Dhivya Sudhan, Belen Rabaglino, Charles Wood, Dietmar Siemann. University of Florida, Gainesville, FL; Universidad Nacional de Rio Cuarto, Argentina
Abstract: 4185
Date/Time/Location: Tuesday, April 21, 2015, 1:00 PM - 5:00 PM (ET), Section 19


OXiGENE is a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer. The company is focused on developing vascular disrupting agents (VDAs), which are compounds that selectively disrupt abnormal blood vessels associated with solid tumor survival and progression. The company's lead clinical product candidate, fosbretabulin, is in development as a potential treatment for solid tumors. OXi4503, its second product candidate, is in development for acute myeloid leukemia (AML). OXiGENE is dedicated to leveraging its intellectual property and therapeutic development expertise to bring life-extending and life-enhancing medicines to patients.
CONTACT: Investor and Media Contact:         650-635-7000

company logo